ArticleChinese medical journal2026
g BRCA1 and g BRCA2 mutations in specific different domains affect ovarian cancer prognosis: A multicenter retrospective study.
Article in Chinese medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognostic value of germline BRCA1/2 mutations (g BRCA1/2 m) in ovarian cancer is controversial, and the clinical implications of specific mutation domains within BRCA1/2 remain underexplored. This study aimed to investigate the impact of distinct g BRCA1/2 m domains on survival outcomes in patients with ovarian cancer.
methodsThis multicenter retrospective study, conducted between 2010 and 2022 at three major academic centers in China, analyzed 313 patients with epithelial ovarian cancer with pathogenic g BRCA1/2 m. We evaluated associations between g BRCA1/2 m domains and clinical outcomes including progression-free survival (PFS) and platinum-free interval.
resultsPatients who received platinum-based chemotherapy without maintenance therapy with BRCA1 C-terminal domain 1 (BRCT1) mutations showed significantly prolonged PFS (37.8 vs . 22.6 months; hazard ratio [HR], 0.43; 95% confidence interval [CI], 0.19-0.99; P = 0.042), whereas those with Really Interesting New Gene (RING) mutations had shorter PFS (13.1 vs . 23.2 months; HR, 1.82; 95% CI, 0.89-3.72; P = 0.097). In the subgroup of gross residual disease, RING mutations were significantly associated with reduced PFS (12.9 vs . 21.8 months; HR, 3.25; 95% CI, 1.29-8.18; P = 0.008). A higher likelihood of primary platinum-refractory disease (odds ratio, 7.78; 95% CI, 1.25-48.31; P = 0.028) was observed. Across all mutation locations, poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy demonstrated benefits, notably for patients with BRCA1 RING mutations (HR, 0.10; 95% CI, 0.01-0.84; P = 0.010) and BRCA2 RAD51-binding domain (RAD51-BD) mutations (HR, 0.29; 95% CI, 0.11-0.79; P = 0.010).
conclusionsBRCA1 BRCT1 mutations are associated with improved prognosis following platinum-based chemotherapy, whereas BRCA1 RING domain mutations are linked to a heightened risk of primary platinum-refractory disease. Our findings underscore the need for complete resection with no gross residual disease in patients harboring RING mutations. Furthermore, PARPi maintenance therapy exhibits variable efficacy based on mutation location, with BRCA1 RING and BRCA2 RAD51-BD mutations conferring significant benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.